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The Relevance of Leukotriene B4 to the Development of Acute Lung Injury
Induced by Lipopolysaccharide
Kozo Hidaka and Yuichi Ishibe
Department of Anesthesiology and Reanimatology, Faculty of Medicine, Tottori University,
Yonago 683-0826, Japan
Acute lung injury (ALI) induced by lipopolysaccharide (LPS) develops by the activation
of leukocytes via various mediators.  Leukotriene B4 (LTB4) has a strong effect on
activation and migration of leukocytes. We investigated the role of LTB4 in the chain
leading to the development of ALI induced by LPS, by observing how an LTB4 receptor
antagonist, ONO-4057, suppresses or mitigates leukocyte activation and migration.  The
36 rabbits used in the experiment were divided into 3 groups:  C group (control group
of 12 rabbits treated with physiological saline solution only); L group (of 12 rabbits
treated with 20 µg/kg LPS) and L-O group (of 12 rabbits treated with, first, 10 mg/kg
ONO-4057, then LPS).  Blood samples were taken before, 3 h after and 6 h after the
injection of drugs; then the rabbits were exsanguinated.  The right and left lungs were
removed for wet/dry weight ratio and bronchoalveolar lavage fluid (BALF)
measurements, respectively.  We measured: the leukocyte counts in the peripheral blood,
the chemiluminescence (CL) intensity to measure the amount of oxygen free radical
species (active oxygen species) production, the LTB4 concentration in the blood, the
complement activity levels (CH50), the polymorphonuclear neutrophil elastase (PMN-
E) and myeloperoxidase (MPO) levels in BALF, and the wet/dry weight ratio of the
right lung.  The leukocyte counts in L and L-O rabbits decreased significantly  3 h after
LPS injection, then were regained by the 6th h.  Regarding CL (with and without
zymosan stimulation), there was no significant difference over time for C group.  For L
group, the zymosan-stimulated CL showed a significant increase at the 6th h, whereas
the non-stimulated CL showed significant increases at the 3rd and 6th h.  For L-O
group, the zymosan-stimulated CL showed a significant increase at the 6th h, whereas
the non-stimulated CL increased after 3 h, then slightly decreased after 6 h.  The LTB4
levels showed significant increases at the 6th h for both L and L-O groups.  The CH50
showed significant decreases at 6th h for both L and L-O groups.  The MPO activity in
the BALF was significantly high for both the L and L-O groups.  There was a tendency
for a high PMN-E level in the BALF for L group.  The mean wet/dry weight ratio of the
right lung was significantly high for L group, compared to both C and L-O groups.
Although an inhibitory effect on LTB4 receptors by ONO-4057 failed to prevent
leukocyte migration, it successfully suppressed the activity of non-stimulated CL, MPO
and PMN-E, and, as a result, prevented the wet/dry weight ratio from increasing.
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Acute lung injury (ALI) or acute respiratory
distress syndrome (ARDS) is caused, to a large
extent, by infections or endotoxemia by the
endotoxin, lipopolysaccharide (LPS) (Knaus et
al., 1994).  Finding possible treatments for them is
a subject of paramount clinical importance.  LPS
stimulates macrophages, resulting in production
of humoral factors such as tumor necrosis factor
(TNF), interleukin-1 (IL-1), interleukin-8 (IL-8),
leukotriene B4 (LTB4) and so on (Said and
Hussein, 1989).  These factors further stimulate
lymphocytic activity, resulting in the production
K. Hidaka and Y. Ishibe
46
of various mediators, which then form networks
of their own by interacting with one another
(Schlag and Redl, 1996).  These mediator net-
works further aggravate inflammations, which
cause activation of neutrophils.  Also, LPS direct-
ly activates alternative complement pathways
(Said and Hussein, 1989).  The neutrophils acti-
vated by LPS accumulate in the lungs (Pawe et
al., 1982), then produce polymorphonuclear
neutrophil elastase (PMN-E) and oxygen free rad-
ical species via myeloperoxidase (MPO) activity
(Idell et al., 1985; Said and Hussein, 1989).
Neutrophils normally act in defense of the body
but, if activated excessively, migrate into the inter-
stitum and alveoli and cause tissue damage, and
ultimately ALI.  In order to prevent or minimize
the ill effects of neutrophils, therefore, the chain
of neutrophil activation (described above) must
be broken (Fisher et al., 1994).  Among the media-
tors, the complement C5a, TNF-α, IL-1, IL-8,
platelet activating factor (PAF), LTB4, etc. are
considered to be the major causes of ALI be-
cause of their strong effect on neutrophil acti-
vation and migration (Van Zee et al., 1991;
Vandermeer et al., 1995; Belcastro et al., 1996).
However, the role played by LTB4, which is a
metabolic product of arachidonic acid and 5-
lipoxygenase, in LPS-induced ALI (Palmblad
et al., 1981; Yoshimura et al., 1994) has not
been adequately studied so far.  ONO-4057 was
developed as an LTB4 receptor antagonist.  In
vitro and in vivo, ONO-4057 has been shown to
be effective in inhibiting leukocyte migration
and degranulation; and in dermatitis experi-
ments, it was shown to have an inhibitory effect
on MPO activity (Kishikawa et al., 1992).
In this paper, we report on the results of our
experiment designed to investigate the role
played by LTB4 in the chain leading to the
development of ALI triggered by LPS, by ob-
serving how an LTB4 receptor antagonist,
ONO-4057, suppresses or mitigates leukocyte
activation and migration.
Materials and Methods
The animal experiment reported here was done
in conformity with the ethical guidelines per-
taining to animal experiments, observed by the
Faculty of Medicine, Tottori University.  We
used 36 rabbits (Japanese White rabbits; fe-
male; range of weight, 1.7-2.9 kg), which were
randomly divided into 3 groups: C group (con-
trol group of 12 rabbits to be treated with phys-
iological saline solution only); L group (of
which 12 rabbits were to be injected with LPS)
and L-O group (of which 12 rabbits were to be
treated with ONO-405 first, and then LPS).  Ini-
tially, a sample of 7 mL of blood was taken
from the ear vein of each rabbit in the 3 groups
before the administration of the drugs.  The C
group rabbits, then, were given 12 mL of phys-
iological saline solution.  The L group rabbits
were given 7 mL of physiological saline solu-
tion and 5 mL of LPS solution (E.coli B8.,
Difco, Detroit, MI; LPS 20 µg per each kg of
rabbit weight, µg/kg, dissolved into physio-
logical saline solution).  The L-O group rabbits
were given, first, 5 mL of ONO-4057 (10 mg/
kg) solution (20 mg/mL, dissolved into 7%
NaHCO3, to which physiological saline solu-
tion was added to make the total to 5 mL); then,
they were given 2 mL of physiological saline
solution for 2 min intravenously; and finally,
they were given 5 mL of LPS solution (20 µg/
kg) through the ear vein.  We let the rabbits free
in the cages until the next blood sampling time.
Three h after the initial drug administration,
another sample of 2 mL of blood was taken
from the ear vein; then the rabbits were given 2
mL of physiological saline solution intravenously.
We let them free again.  Six hours after the LPS
injection, a sample of 7 mL of blood was taken
from the ear vein.  The rabbits, then, were given
20 mg/kg of pentobarbital intravenously, and
were anesthetized by 50 mg/kg of ketamine via
muscle injection.  Then we initiated tracheo-
tomy on the rabbits locally anesthetized with
1% lidocaine.  Breathing was controlled by in-
serting a tube endotracheally and using a venti-
lator for small animals (Model 681, Harvard
Apparatus, South Natic, MA) set at 20 respira-
tions/min, 6 mL of room air per kg body weight,
and 2 cm H2O of positive end-expiratory pres-
sure.  The sternum (locally anesthetized with
1% lidocaine) was cut in the middle and, with
the thorax open, the pericardium was opened,
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Abbreviations:  ALI, acute lung injury; ARDS, acute respiratory distress syndrome; BALF, bronchoalveolar lavage
fluid; CH50, complement activity levels; CL, chemiluminescence; IL, interleukin; LPS, lipopolysaccharide; LTB4,
leukotriene B4; MPO, myeloperoxidase; PAF, platelet activating factor; PMN-E, polymorphonuclear neutrophil
elastase; TNF, tumor necrosis factor
and the right ventricle was incised for exsangui-
nation.  The heart and the lungs (with the res-
piration tube inserted) were taken outside the
body as a unit.  The right hilum was ligated, and
the right lung was removed for wet/dry weight
measurement.  Twenty milliliters of physiological
saline solution (5 mL over 4 times) were infused
into the left lung through the main trachea; then
a sample of 12–15 mL of bronchoalveolar la-
vage fluid (BALF) was taken from the left lung.
The measurements were the leukocyte
counts in the peripheral blood; the chemilumi-
nescence (CL)/leukocyte (n = 6 with zymosan
stimulation and n = 6 without, for each group)
to measure the amount of oxygen free radical
species production; the LTB4 levels (n = 8 for C
group; n = 9 for L group and n = 9 for L-O
group); the complement activity levels (CH50);
the PMN-E and MPO activity levels, from the
supernatants of the BALF, centrifuged at 1000
rpm, 10 min.  The leukocytes were counted by
Celltac (MEK-5158, Nihon Kohden, Tokyo,
Japan).  For CL, a Luminescence Reader (BLR-
201, ALOKA, Tokyo) was used to measure the
50-min luminescence of the 0.1 mL of heparin-
added blood in 1.2 mL of luminol-HEPES buf-
fer solution (14 mM HEPES, pH 7.4, containing
66 mM of luminol), stirred at 37˚C.  Zymosan-
stimulated CL was measured when 0.1 mL of
40 mg/mL non-opsonized zymosan (zymosan
A: Sigma Chemical Co., St. Louis, MO) was
added; and non-zymosan-stimulated CL, with-
out it.  LTB4 was measured by the Radio Immuno
Assay method (Mitsubishi Chemical BCL,
Tokyo).  Complement activity was measured by
the CH50 method (SRL Inc., Tokyo).  PMN-E
activity in the BALF (0.5 mL) was measured by
the hydrolysis method of Yoshimura and co-
workers (1994):  the hydrolysis of the substrate,
250 µM of L-hydroglutamyl-L-propyl-L-valin-p-
nitroanilide (Dai-ichi Chemicals, Tokyo), was
measured by a Multiskan MS (Labsystems,
Basingstroke, Helsinki, Finland) at 405 nm,
following the incubation with a Tris buffer (25
mM, pH 8.3) at 37˚C for 4 h.  MPO activity in
the BALF (0.5 mL) was measured by the
methods described previously (Henson et al.,
1978; Belcastro et al., 1996):  The absorption
density of o-dianisidine (96 µg/mL) was mea-
sured by the Multiskan MS at 480 nm (extinc-
tion coefficient: 1.13 × 104/M), following
incubation with phosphorous buffer (38 mM,
pH 6.2) and 0.0038% H2O2 at 37˚C for 15 min.
The measured values are expressed as mean
and SEM.  The statistical analysis was perform-
ed by an analysis of variance, followed by
Scheffé’s test (for differences among groups) and
a paired Student’s t-test (for differences within
groups).  A P value of less than 0.05 was con-
sidered statistically significant.
Results
There was no statistically significant difference
in the weights of the rabbits among all groups.
There was no significant difference over
time in leukocyte counts for C group, whereas
the leukocyte counts for L and L-O groups de-
creased significantly after 3 h, but they regained
after 6 h (Fig. 1).
Regarding CL (with and without zymosan
stimulation), there was no significant difference
Fig. 1.  Changes in leukocyte counts for the 3 groups (n
= 12, mean ± SEM, for each group).  *Versus the pre-
vious counts of the same group (P < 0.05); **versus the
counts in the control group at each time (P < 0.05).  ,
C group (control group); , L group (20 µg/kg LPS); ,
L-O group (20 µg/kg LPS and 10 mg/kg ONO-4057).
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Fig. 2.  Changes in chemiluminescence (CL) inten-
sity with zymosan stimulation for the 3 groups (n =
6, mean ± SEM, for each group).  *Versus the
previous intensity of the same group (P < 0.05);
**versus the intensity of the control group at each
time (P < 0.05).  , C group (control group); , L
group (20 µg/kg LPS); , L-O group (20 µg/kg LPS
and 10 mg/kg ONO-4057).
Fig. 3.  Changes in chemiluminescence (CL) inten-
sity without zymosan stimulation for the 3 groups (n
= 6, mean ± SEM, for each group).  *Versus the
previous intensity of the same group (P < 0.05);
**versus the intensity of the control group at each
time (P < 0.05).  , C group (control group); , L
group (20 µg/kg LPS); , L-O group (20 µg/kg LPS
and 10 mg/kg ONO-4057).
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over time for C group.  The zymosan-stimulated
CL for L group showed a significant increase
from 4.214 ± 1.397 kCounts/leukocyte count
(before LPS injection) to 14.952 ± 0.965 (6 h
after), whereas the non-stimulated CL showed a
significant increase from 0.728 ± 0.210 (before
LPS injection) to 1.097 ± 0.320 (3 h after), then
to 1.554 ± 0.467 (6 h after) (Figs. 2 and 3).  Sim-
ilarly, the zymosan-stimulated CL for L-O
group showed a significant increase from 4.556
± 0.934 (before LPS infusion) to 15.648 ± 4.168
(6 h after) (Fig. 2), whereas the non-stimulated
CL increased from 0.732 ± 0.234 (before LPS
injection) to 1.170 ± 0.245 (after 3 h), but it de-
creased to 0.963 ± 0.235 (after 6 h) (Fig. 3).
The intergroup comparisons show that the
zymosan-stimulated CL for L and L-O groups
(6 h after LPS injection) was significantly
higher than that for C group, whereas the non-
stimulated CL for L group (3 and 6 h after) was
significantly higher than that for C group, and
the non-stimulated CL for L-O group (3 h after)
was significantly higher than that for C group
(Figs. 2 and 3).
While there was no significant difference in
LTB4 (before and 6 h after LPS injection)
among all groups, the LTB4 for L and L-O
groups showed significant increases from
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Fig. 4.  Changes in leukotriene B4 (LTB4) concen-
tration for the 3 groups (n = 12, mean ± SEM, for
each group). *Versus the previous concentration of
the same group (P < 0.05).  , C group (control
group); , L group (20 µg/kg LPS); , L-O group
(20 µg/kg LPS and 10 mg/kg ONO-4057).
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Fig. 5.  Changes in complement activity for the 3
groups (n = 12, mean ± SEM, for each group).
*Versus the previous activity of the same group (P <
0.05).  , C group (control group); , L group (20
µg/kg LPS); , L-O group (20 µg/kg LPS and 10
mg/kg ONO-4057).
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Fig. 7.  Polymorphonuclear neutrophil elastase
(PMN-E) activity of bronchoalveolar lavage fluid
(BALF) for the 3 groups (n = 12, mean ± SEM, for
each group).  , C group (control group); , L group
(20 µg/kg LPS); , L-O group (20 µg/kg LPS and 10
mg/kg ONO-4057).
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Fig. 6.  Myeloperoxidase (MPO) activity of bron-
choalveolar lavage fluid (BALF) for the 3 groups (n
= 12, mean ± SEM, for each group).  **Versus the
control group (P < 0.05).  , C group (control
group); , L group (20 µg/kg LPS); , L-O group
(20 µg/kg LPS and 10 mg/kg ONO-4057).
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Fig. 8.  Wet/dry ratios of the 3 groups (n = 12, mean
± SEM, for each group).  **Versus the control group
(P < 0.05).  †Versus the L-O group (P < 0.05).  , C
group (control group); , L group (20 µg/kg LPS);
, L-O group (20 µg/kg LPS and 10 mg/kg ONO-
4057).
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121.12 ± 12.91 and 123.91 ± 12.88 pg/mL blood
(before LPS injection) to 155.86 ± 19.89 and
166.89 ± 20.11 (6 h after), respectively (Fig. 4).
Regarding the CH50 for C group, there was
no significant difference between the time be-
fore physiological saline solution was given
(6.5 ± 0.6 U/mL) and the time 6 h later (6.1 ±
0.5), whereas for L and L-O groups, CH50
showed significant decreases from 6.4 ± 0.4 and
6.4 ± 0.6 (before LPS injection) to 4.9 ± 0.6 and
5.0 ± 0.8 (6 h after), respectively (Fig. 5).
The MPO level in the BALF for C group
was 1.77 ± 1.50 × 10-6 M/mL BALF, whereas
those for L and L-O groups were significantly
higher at 8.54 ± 1.11 and 6.38 ± 1.03, respec-
tively; and the MPO of L-O group tended to be
lower (P = 0.17) than that for L group (Fig. 6).
Although there was no significant differ-
ence in PMN-E in the BALF among groups, the
PMN-E for L group tended to be higher (7.22 ±
2.36 U/mL BALF) in contrast with those for C
group (6.85 ± 0.98, P = 0.26) and L-O group
(6.76 ± 1.63, P = 0.25) (Fig. 7).
The mean wet/dry weight ratio for L group
was significantly higher (5.13 ± 0.06) than
those for C group (4.93 ± 0.06) and L-O group
(4.98 ± 0.04) (Fig. 8).
Discussion
Our experiment showed that:  i) ONO-4057 did
not block leukocyte migration caused by LPS;
ii) while ONO-4057 did not have an effect on
the zymosan-stimulated CL of leukocytes (6 h
after LPS injection), it inhibited the non-stimu-
lated CL; iii) there was a tendency for ONO-
4057 to inhibit PMN-E and MPO activities in
the BALF; and iv) ONO-4057 successfully in-
hibited the increase in wet/dry weight ratio.
The experiments using guinea pigs by
Kishikawa and coworkers (1992) showed that
ONO-4057 inhibited the LTB4-induced leuko-
penia in the peripheral blood in a dose-depen-
dent manner,  effective when 10 mg/kg or more
were ingested and when 0.3 mg/kg or more were
given intravenously.  In our experiment, the
rabbits received intravenous injection of 10 mg/
kg of ONO-4057 2 min before LPS was injected
intravenously.  The reason for our decision to
use 10 mg/kg of ONO-4057 this time is because
there were 3 rabbits which were given 5 mg/kg
of ONO-4057, but which did not show any
effect of ONO-4057 to inhibit the LPS-induced
decrease in leukocyte count; and the rabbits
which were only given 10 mg/kg of ONO-4057
did not die nor did they show any signs of
abnormality such as weakness or a lowering of
their activity level.  From these observations,
**
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we decided to try 10 mg/kg of ONO-4057, expect-
ing sure signs of the effectiveness of ONO-
4057.
We decided on the dosage of LPS to be 20
µg/kg, which was the dosage inferred from our
preparatory experiments, to be maximally
effective without adversely affecting the design
of our experiment.  We also decided that our
observation time should be 6 h, on the basis of
the significant results of other experiments in
which observation time was 6 h, to measure the
effectiveness of certain drugs in inhibiting the
activation of neutrophil elastase (Kubo et al.,
1994; Nishina et al., 1997), and by taking into
consideration the time it takes for various kinds
of cytokines to be produced (Sakamoto et al.,
1994; Salvemini et al., 1995; Nishina et al., 1997).
It has been reported that the concentration
level of LTB4 after LPS injection is inferred to
have 2 phases of change:  the peak of LTB4 at
an earlier stage (1 h after) is induced by macro-
phages in the blood, whereas the LTB4 peak at a
later stage (4 h after) is due to the leukocytes
accumulated in the lungs (Kobayashi et al.,
1993).  In our experiment, the LTB4 concen-
tration levels for L and L-O groups showed in-
creases at 6 h, thus not showing the effective-
ness of ONO-4057 in inhibiting the production
of LPS-induced LTB4.  We speculate that this
was due to the fact that although ONO-4057
might have had an effect on LTB4 receptors,
neutrophils could still have produced LTB4 by
other means (such as via complements, PAF, con-
centrated IgG, TNF, etc.) (Fogh et al., 1992).
It has been reported that with the rabbits
injected with LPS intravenously, there was an
accumulation of leukocytes in the lungs and
liver (after 2 h) and decreases in the leukocyte
count in the peripheral blood, the bone marrow,
and the spleen (Toft et al., 1994).  From our pre-
paratory experiments we knew that the injection
of LPS into rabbits decreased their leukocyte
count in the peripheral blood after 5 min; this
proved to be true for the L group in our present
experiment.  Also, the leukocyte count even for
L-O group, like L group, significantly decreas-
ed 3 h after LPS injection, and ONO-4057 fail-
ed to inhibit leukocyte migration.
The amount of complement activity for L
and L-O groups significantly decreased 6 h
after LPS injection.  We conjecture that this was
due to the fact that the leukocytes accumulated
in the liver as well as in the lungs, and damaged
the liver; and the production of complements in
the liver could not catch up with the consump-
tion of LPS-induced complements (Arai et al.,
1989).
The non-stimulated CL intensity for L-O
group (as well as that for L group) showed a
high value at 3 h; but it became lower after 6 h.
This, together with the fact that the LTB4 for L-
O group (as well as that for L group) was high at
6 h, indicates that there was a factor other than
LTB4 that contributed to the production of an
oxygen free radical species.  LPS, directly and
indirectly, stimulates and produces various
mediators and cytokines.  It also stimulates C3
directly, and activates alternative complement
pathways (Said and Hussein, 1989).  We think
that the higher non-stimulated CL intensity
levels of L and L-O groups, compared to the
level of C group, at 3 h, were due to the fact that
complements were directly stimulated by LPS
and the neutrophil activity increased because of
other mediators and cytokines.
Zymosan activates complement compo-
nents (after C3) via properdin-related factors.
The zymosan-stimulated CL intensity levels for
all groups before treatments and C group at 3
and 6 h were about 10 times higher than their
non-stimulated CL counterparts.  This can be
explained by saying that the complements in the
blood reacted to zymosan.
The zymosan-stimulated CL intensity levels
for L and L-O groups were significantly high at
6 h, and the non-stimulated CL level of L-O
group decreased after 6 h.  This can be explain-
ed in terms of the Second Attack Theory
(Ogawa, 1996).  According to the theory, we
can say that the LPS in L and L-O groups
heightened the responsiveness of the neutro-
phils, which zymosan further stimulated as a
second attack, resulting in more production of
oxygen free radical species and, consequently,
an increase in CL.  The amount of oxygen free
radical species production in the peripheral blood
in L-O group, when no additional zymosan-
induced stimulation was present, can be known
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from the amount of oxygen free radical species
production without zymosan stimulation at 6 h.
We can attribute to the effectiveness of ONO-
4057 the fact that the production capacity of
oxygen free radical species from leukocytes in
the peripheral blood is lower for L-O group than
for L group.  From these facts, we inferred that
ONO-4057 had an inhibitory effect on LTB4
receptor activity and, thus, helped lower the
production of oxygen free radical species from
neutrophils; but ONO-4057 failed to control the
LPS-heightend responsiveness of neutrophils.
The levels of the MPO and PMN-E for L-O
group tended to be lower than those for L group,
indicating a weak positive effect of ONO-4057.
The amount of oxygen free radical species in-
creases and decreases, depending on whether
PMN-E is present or not, respectively (Kusner and
King, 1989).  Also, one of the PMN-E inhibitors,
α1-protease inhibitor (α1-PI), becomes in-
activated in the presence of oxygen free radical
species (Tanaka et al., 1991).  Thus, oxygen free
radical species and PMN-E influence each other.
The wet/dry weight ratio indicates an increase in
vascular permeability (Suzuki et al., 1994) due to
the damage done to endothelial cells (Tate and
Repine, 1983) jointly by oxygen free radical
species and PMN-E.  The results of our experi-
ment indicate that ONO-4057 must have had an
inhibitory effect (up to 6 h) on the LPS-induced
increase in vascular permeability in the lungs.
From the above discussion, we can say that
ONO-4057 was effective against lung injuries
caused by LPS, but with a few limitations.
First, the intravenous injection of ONO-4057
caused our rabbits to show signs of pain, and
death in some cases with LPS after ONO-4057
injection.  We used ONO-4057 diluted in phys-
iological saline solution and injected it slowly,
but there is a possibility that the pain caused by
ONO-4057 injection might have led to the pro-
duction of various mediators, cytokines, etc.
Also, while LPS 20 µg/kg alone did not kill any
rabbits, pretreatment with ONO-4057 killed 3
out of 15 rabbits within 1.5 h to 2 h.  However,
the rabbits given LPS alone were weak, suffer-
ing from diarrhea, whereas the rabbits which
were pretreated with ONO-4057 and which sur-
vived 6 h until the end of the experiment, exhib-
ited no sign of diarrhea or any abnormality.  We
know that the lethal dose of ONO-4057 given
intravenously for rats is 300 mg/kg*; but we
lack similar data pertaining to rabbits.  It might
be that for rabbits, the 50% effective dose of
ONO-4057 is very close to the 50% lethal dose.
Also, this might indicate the complexity of
mediator networks.  We speculate that in our
dead rabbit cases, the antagonistic effect of
ONO-4057 was so strong on LTB4 receptors
that LTB4, which is necessary for normal phys-
iological functioning, was inhibited, and conse-
quently, parts of the  mediator networks were
blocked, which caused a malfunction in homeo-
stasis in those dead rabbits.
Conclusions
Although ONO-4057, as an LTB4 receptor ant-
agonist, did not prevent leukocyte migration
caused by LPS, it tended to control the non-
stimulated CL level of leukocytes in the periph-
eral blood, and suppressed the MPO and PMN-
E activity in the BALF, as a result, preventing
the wet/dry ratio from increasing.  From these
results, we conclude that LTB4 must be playing
a role in LPS-caused lung injuries.  However,
our experiment also suggests the possibility that
an inhibitory effect on LTB4 receptors might
adversely lead to the suppression of the natural
protective mechanism by LTB4 against inflam-
mation, and might further lead to the break-
down of mediator networks.
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